GSK plc (GSK.L) Stock Price

GSK plc Price

LSE·CLOSED
18.45
​
Market closed

Over the last 19 years GSK plc grew revenue by 1.8% annually, reaching 32.67 B GBP. Earnings per share have grown at 0.8% per year over the last 19 years. For GSK plc, the net margin of 17.5% is broadly stable versus 17.8% a few years ago. At today's price the dividend yield works out to roughly 4.55%. The payout ratio is around 46% of earnings. The dividend has grown at 1.8% per year over the past 19 years. The consensus 12-month price target for GSK plc is 1,861.50 GBP, about 9,989.4% above where the stock trades today. Of 32 analysts, 14 rate the stock a buy — an overall Hold consensus.

GSK plc stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc business model & stock analysis

GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership.

Frequently asked questions about GSK plc

Analysts currently set an average price target of 1,893.63 GBP for the GSK plc stock (median: 1,861.50 GBP), implying +2.6 % versus the latest price. The consensus is based on 32 analyst ratings.

32 analysts currently rate the GSK plc stock: 14 recommend buying, 14 holding and 4 selling. For 2026, analysts expect GSK plc to generate revenue of 33.85 B GBP and earnings per share of 1.80 GBP.

Converted at the current exchange rate, the GSK plc share trades at 22.12 EUR (18.45 GBP).

The GSK plc share (GSK.L) is listed on 4 stock exchanges, including: London (GSK.L), SIX (Zürich) (GSK.SW), XETRA (GS7.DE), Frankfurt (GS71.F).

The expected revenue of GSK plc is 33.85 B GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of GSK plc is 7.37 B GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of GSK plc is currently 10.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the GSK plc stock.

The price-to-sales ratio (P/S) of GSK plc is currently 2.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the GSK plc stock.

The Eulerpool Quality Score for GSK plc is 7/10.

The ISIN of GSK plc is GB00BN7SWP63. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of GSK plc is 940561. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of GSK plc is GSK.L. The ticker symbol is used to trade GSK plc shares on the stock exchange.

Fair ValueTerminal
18.45 GBP
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
347,277.44 GBP
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website gsk.com
Currency
GBP
Initial public offering
May 22, 1972
ISIN
GB00BN7SWP63
Cusip
G3910J112
Sedol
0925288
Market capitalization
75.96 B GBPLarge Cap
52-Week Range
PEG
8.09
P/E ratio
P/Ee 2026
10.31
P/Ee 2027
9.84
P/Ee 2028
9.38
P/Ee 2029
8.67
P/Ee 2030
8.51
P/S
P/Se
2.23
EV/EBIT
11.60
P/B Ratio
4.64
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
16.76 %
Dividend
Dividend yield
4.55 %
Est. Dividend Yield
3.69 %
Payout Ratio
45.75 %
Dividend growth Ø5Y
-9.41 %
Dividend payments per year
5
Dividend paid since
36 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
0.00 %
Last updated Nov 1, 2026, 11:14 PM

GSK plc Ticker

FRANKFURT · GS71.FLONDON STOCK EXCHANGE · GSK.LSIX · GSK.SWXETRA · GS7.DE

All fundamentals and in-depth analysis of GSK plc

Our stock analysis for GSK plc stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GSK plc. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.